Abstract:

Target: The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) disease (COVID-19) is still showing its effects worldwide as a major problem. The antibodies to SARS-CoV-2 are not yet fully understood, and the clinical benefits of serological tests are uncertain. In this study, antibodies were evaluated by the Roche SARS-CoV-2 antibodies test in different times taken samples of patients who passed COVID-19. Methods: 21 people in our hospital examined the SARS-CoV-2 PCR test between March 2020 and April 2020 and from those who collected serum samples, re-sampleed in July 2020 and a total of 42 samples examined Roche SARS-CoV-2 antibodies levels. Results: In 7 of the first samples of 21 people, anti-SARS CoV 2 antibodies were negative, in 14 anti-SARS CoV 2 antibodies were positive. In all the negative samples, the RT-PCR results were positively identified. In second samples 1 anti-SARS CoV 2 antibodies were negative, and in 20 anti-SARS CoV 2 antibodies were positive. When the second samples of all persons were taken, there was no decline in the SARS-CoV-2 antibodies. The result: even in the second samples there are samples in negative and partially low cut off values. This study is important in terms of the presence and tracking of antibodies and the determination of the level of donor antibodies in plasmaferes.

Keywords: